Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats
- PMID: 9160782
Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats
Abstract
Antisense oligodeoxynucleotides (AS-ODN) can be designed to provide inhibition of a specific protein. Since angiotensin receptors are involved in blood pressure regulation we constructed AS-ODN to angiotensin II type-1 receptor (AT1) mRNA. When given centrally, the AS-ODN reduces blood pressure in spontaneously hypertensive rats (SHR) 24 h after injection. To study the time course of a single AS-ODN injection on blood pressure and heart rate, groups of SHR were injected intracerebroventricularly (icv) with either single dose of AS-ODN or scrambled (SC) ODN and blood pressure was recorded through implanted catheters daily for up to 9 days. Blood pressure decreased significantly in the AS-ODN treated rats compared to the SC-ODN rats for up to 7 days. The maximum decrease (38 mm Hg) occurred at 3 days. There appeared to be no toxic reaction or side effects and the blood pressure level had recovered by days 8 and 9. Heart rate was not altered by AS-ODN treatment. To test that the ODN was entering the brain tissue, fluorescein-isothiocyanate labelled (FITC) ODN was injected in Sprague-Dawley rats and the fluorescence detected 1 h later by confocal microscopy. Within 1 h there was rapid uptake into cells close to the site of injection and into brain parenchyma around the third and lateral ventricles. To test that the AS-ODN had reduced AT1 receptors, binding studies were carried out on membranes from hypothalamic tissue. There was a modest (approximately 20%) but significant (P < .05) decrease in the AT1 receptor binding after 25 microm or 50 microm AS-ODN. AT2 receptors were not altered by the AS-ODN, indicating its specificity for the AT1 receptor. The small decrease in receptor binding, relative to its large effect on blood pressure, is discussed in terms of the AT1 receptor life cycle. The mechanism for the long action of a single AS-ODN injection is hypothesized as resulting from the persistence of AS-ODN in the nucleus, preventing transport of the mRNA into the cytoplasm.
Similar articles
-
Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.Hypertension. 1998 Jun;31(6):1317-23. doi: 10.1161/01.hyp.31.6.1317. Hypertension. 1998. PMID: 9622148
-
Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.Regul Pept. 1993 Dec 10;49(2):167-74. doi: 10.1016/0167-0115(93)90438-e. Regul Pept. 1993. PMID: 8134617
-
Antisense oligonucleotide to AT1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin.Regul Pept. 1994 Dec 15;54(2-3):543-51. doi: 10.1016/0167-0115(94)90551-7. Regul Pept. 1994. PMID: 7716285
-
Somatic gene therapy for hypertension.Braz J Med Biol Res. 2000 Jun;33(6):715-21. doi: 10.1590/s0100-879x2000000600013. Braz J Med Biol Res. 2000. PMID: 10829100 Review.
-
Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid.Am J Cardiol. 1998 Nov 19;82(10A):60S-62S. doi: 10.1016/s0002-9149(98)00680-8. Am J Cardiol. 1998. PMID: 9860363 Review. No abstract available.
Cited by
-
The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease.Drugs. 2000 Aug;60(2):239-48. doi: 10.2165/00003495-200060020-00001. Drugs. 2000. PMID: 10983731 Review.
-
Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons.J Neurosci. 1999 Nov 1;19(21):9218-27. doi: 10.1523/JNEUROSCI.19-21-09218.1999. J Neurosci. 1999. PMID: 10531425 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials